



EFW

PTO/SB/21 (09-04)

Approved for use through 07/31/2006. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

TRANSMITTAL FORM

(to be used for all correspondence after initial filing)

Application Number	10/716,393
Filing Date	November 17, 2003
First Named Inventor	Quan Nguyen
Group Art Unit	1635
Examiner Name	Amy Hudson Bowman
Attorney Docket Number	70-000410US

Total Number of Pages in This Submission **4**

ENCLOSURES (check all that apply)

<input type="checkbox"/> Fee Transmittal Form	<input type="checkbox"/> PTO-1449 Form	<input type="checkbox"/> Interview Summary
<input type="checkbox"/> Fee Attached	<input type="checkbox"/> Cited References	<input type="checkbox"/> Request for Continued Examination (RCE)
<input checked="" type="checkbox"/> Amendment / Response	<input type="checkbox"/> Copy of PCT Search Report	<input type="checkbox"/> Request for Corrected Filing receipt
<input type="checkbox"/> Response to Restriction RequirementX	<input type="checkbox"/> Copy of EP Search Report	<input type="checkbox"/> Copy of Filing Receipt - marked up
<input type="checkbox"/> Affidavits/declaration(s)	<input type="checkbox"/> Petition to Convert to a Provisional Application	<input type="checkbox"/> Status Letter
<input type="checkbox"/> Extension of Time Request	<input type="checkbox"/> Power of Attorney, Revocation Change of Correspondence Address	<input type="checkbox"/> Additional Enclosure(s) (please identify below):
<input checked="" type="checkbox"/> Receipt Acknowledgement Postcard	<input type="checkbox"/> Terminal Disclaimer	
<input type="checkbox"/> Information Disclosure Statement	<input type="checkbox"/> Small Entity Statement	
<input type="checkbox"/> Certified Copy of Priority Document(s)	<input type="checkbox"/> Request for Refund	
<input type="checkbox"/> Response to Missing Parts/ Incomplete Application	Authorization to Charge Deposit Account Please charge Deposit Account No. 50-0893 for any additional fees associated with this paper or during the pendency of this application, including any extensions of time for consideration of the documents enclosed.	
<input type="checkbox"/> Response to Missing Parts under 37 CFR 1.52 or 1.53	<div>Remarks</div>	

SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT

Firm or Individual name	Jonathan Alan Quine, Reg. No. 41,261, Quine Intellectual Property Law Group, P.C.		
Signature			
Date	March 20, 2007		

CERTIFICATE OF MAILING

I hereby certify that this correspondence is being facsimile transmitted to the USPTO or deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on the date shown below.

Typed or printed name	Amelia Weintraub		
Signature		Date	March 20, 2007



CERTIFICATE OF MAILING

I hereby certify that this correspondence is being deposited with the United States Postal Service first class mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on March 20, 2007.

QUINE INTELLECTUAL PROPERTY LAW GROUP, P.C.

By: *A. Weintraub*

Amelia Weintraub

Appl. No. : 10/716,393
Applicant : Quan Nguyen, et al.
Filed : November 17, 2003
TC/A.U. : 1635
Examiner : Amy Hudson Bowman

Confirmation No. 4409

Docket No. : 70-000410US
Customer No. : 22798

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

In response to the Restriction Requirement mailed February 20, 2007, Applicants elect to prosecute Group I (claims 103, 105-113, 116-129, and 131-142) with traverse.

In response to the requirement to elect a single disclosed species, Applicants elect: for cellular delivery module (claims 132 and 135), a polypeptide; and for label configuration (claims 125-126 and 128-129), the labeled RNA comprising two fluorescent labels, a donor and an acceptor, where the donor is attached to the first polyribonucleotide and the acceptor is attached to the second polyribonucleotide.

Claims 103, 105-113, 116-123, 127-129, 131-134, and 136-142 read on the elected species.

Applicants' understanding is that the procedures of MPEP 803.02 will be followed, in that non-elected species will be examined if the elected species is found to be patentable.